Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2018-99-119944

Published: 2018

Journal Articles

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Gregory P. Coffey, PhD, Jiajia Feng, MD, Andreas Betz, PhD, Anjali Pandey, PhD, Matt Birrell, B.S., Janet M. Leeds, PhD, Kenneth Der, PhD, Sabah Kadri, PhD, Pin Lu, PhD, Jeremy Segal, PhD, Lynn Wang, MD PhD, Glenn Michelson, MD, John T Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 2782.

https://doi.org/10.1182/blood.V130.Suppl_1.2782.2782

Published: 2017

Journal Articles

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Matthew D Blunt, PhD, Rachel Dobson, BSc(Hons), Lindsay D Smith, PhD, Jonathan C. Strefford, Pamela B. Conley, PhD, Anjali Pandey, PhD, Andrew J Davies, FRCP PhD, Peter M Johnson, MA, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Greg P Coffey, PhD, Andrew J Steele, PhD

Blood (2016) 128 (22): 351.

https://doi.org/10.1182/blood.V128.22.351.351

Published: 2016

Journal Articles

Dual SYK/JAK Inhibition Overcomes Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Yue Lynn Wang, MD PhD, Pin Lu, PhD, Greg P Coffey, PhD, Anjali Pandey, PhD, Ailin Guo, PhD MD

Blood (2016) 128 (22): 5377.

https://doi.org/10.1182/blood.V128.22.5377.5377

Published: 2016

Journal Articles

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Greg P Coffey, PhD, Jiajia Feng, MD, Sabah Kadri, PhD, Y. Lynn Wang, MD PhD, Pin Lu, PhD, Shruti Sharma, PhD, Jeremy Segal, PhD, Glenn Michelson, MD, Anjali Pandey, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 2768.

https://doi.org/10.1182/blood.V128.22.2768.2768

Published: 2016

Journal Articles

Predicting Cerdulatinib Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates

Greg P. Coffey, PhD, Jiajia Feng, MD, Glenn Michelson, MD, Janet Leads, PhD, John T. Curnutte, MDPhD, Anjali Pandey, PhD, Pamela B. Conley, PhD

Blood (2015) 126 (23): 3706.

https://doi.org/10.1182/blood.V126.23.3706.3706

Published: 2015

Journal Articles

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

Paul A Hamlin, Jr., MD, Ian Flinn, MD, Nina wagner-Johnston, MD, Jan A Burger, MD PhD, Glenn Michelson, MD, Anjali Pandey, PhD, Matt Birrell, Greg P. Coffey, PhD, Janet M Leeds, PhD, John T. Curnutte, MDPhD, Manish R. Patel, MD

Blood (2015) 126 (23): 3929.

https://doi.org/10.1182/blood.V126.23.3929.3929

Published: 2015

Journal Articles

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Manish Patel, Paul Hamlin, MD, Donald K Strickland, MD, Anjali Pandey, PhD, Greg Coffey, PhD, Janet M Leeds, PhD, Gallia G. Levy, MD PhD, John T. Curnutte, MDPhD, Nina Wagner-Johnston, Ian W. Flinn, MD

Blood (2014) 124 (21): 3103.

https://doi.org/10.1182/blood.V124.21.3103.3103

Published: 2014

Journal Articles

SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor

Y. Lynn Wang, MD PhD, Jiao Ma, PhD, Wei Xing, PhD, Pin Lu, MD PhD, Karen Dresser, Ailin Guo, PhDMD, Anjali Pandey, PhD, Pamela B. Conley, PhD, Hongbo Yu, MD PhD, Greg Coffey, PhD

Blood (2014) 124 (21): 926.

https://doi.org/10.1182/blood.V124.21.926.926

Published: 2014

Journal Articles

Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity In Both ABC and GCB Types Of Diffuse Large B Cell Lymphoma

Jiao Ma, PhD, Greg Coffey, PhD, Pin Lu, MD, PhD, Shuhua Cheng, PhD, Ailin Guo, MD, PhD, Anjali Pandey, PhD, Y. Lynn Wang, MD, PhD

Blood (2013) 122 (21): 1833.

https://doi.org/10.1182/blood.V122.21.1833.1833

Published: 2013

Journal Articles

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Stefan KÖhrer, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y Rosin, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, Medhat Shehata, Ulrich Jäger, Susan M. O'Brien, MD, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Deborah Thomas, MD, Hagop M Kantarjian, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3532.

https://doi.org/10.1182/blood.V120.21.3532.3532

Published: 2012

Journal Articles

PRT062070: A Dual Syk/JAK Inhibitor with Potent Immune Regulatory Capacity in Rodent Models of Inflammation and Cancer.

Greg Coffey, PhD, Francis DeGuzman, PhD, Gail Lee, BS, Lynn Kamen, PhD, Dale Baker, PhD, Stanley J Hollenbach, BS, JD, Anjali Pandey, PhD, Uma Sinha, PhD

Blood (2012) 120 (21): 2764.

https://doi.org/10.1182/blood.V120.21.2764.2764

Published: 2012

Journal Articles

Specific Inhibition of Syk Suppresses Leukocyte Immune Function and Alleviates Inflammation In Rodent Models of Rheumatoid Arthritis

Greg Coffey, PhD, DeGuzman Francis, Ph.D., Mayuko Inagaki, Yvonne Pak, Suzanne Delaney, Andreas Betz, Zhaozhong J Jia, Qing Xu, Shawn Bauer, Yonghong Song, Anjali Pandey, PhD, Dale Baker, DVM, PhD, Stanley Hollenbach, David R. Phillips, PhD, Uma Sinha, PhD

Blood (2010) 116 (21): 1727.

https://doi.org/10.1182/blood.V116.21.1727.1727

Published: 2010

Journal Articles

Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

Julia Hoellenriegel, Greg Coffey, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, William G. Wierda, MD, PhD, Michael J Keating, MD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 3604.

https://doi.org/10.1182/blood.V116.21.3604.3604

Published: 2010

Journal Articles

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

Stephen Spurgeon, MD, Luke B Fletcher, Jeffrey W Tyner, PhD, Brian J Druker, MD, Anjali Pandey, PhD, Uma Sinha, PhD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2839.

https://doi.org/10.1182/blood.V116.21.2839.2839

Published: 2010

Journal Articles

PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model

Michael P. Reilly, PhD, Uma Sinha, PhD, Pierrette Andre, Scott M. Taylor, MS, Yvonne Pak, PhD, Francis R. DeGuzman, Nisha Nanda, PhD, Anjali Pandey, PhD, Steven E. McKenzie, MD, PhD

Blood (2008) 112 (11): 269.

https://doi.org/10.1182/blood.V112.11.269.269

Published: 2008

Journal Articles

Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy

Suzanne Delaney, PhD, Uma Sinha, PhD, Nisha Nanda, PhD, Yibing Yan, PhD, Anjali Pandey, PhD, Stan Hollenbach, Whyte Owen, PhD, David Phillips, PhD, Patrick Andre, Ph.D.

Blood (2008) 112 (11): 409.

https://doi.org/10.1182/blood.V112.11.409.409

Published: 2008

NARROW

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Dual SYK/JAK Inhibition Overcomes Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Predicting Cerdulatinib Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor

Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity In Both ABC and GCB Types Of Diffuse Large B Cell Lymphoma

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

PRT062070: A Dual Syk/JAK Inhibitor with Potent Immune Regulatory Capacity in Rodent Models of Inflammation and Cancer.

Specific Inhibition of Syk Suppresses Leukocyte Immune Function and Alleviates Inflammation In Rodent Models of Rheumatoid Arthritis

Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model

Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only